Kiora Pharmaceuticals, Inc. — Q3 2023 Form 10-Q Summary
Business Context and Reporting Period
Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing therapies for orphan retinal diseases. The filing covers the three and nine months ended September 30, 2023, with unaudited U.S. GAAP financial statements. The company has not generated significant revenue and remains focused on research, clinical development, partnering and capital raising.
- Lead program: KIO-301, a potential vision-restoring photoswitch for retinal degeneration, with development expanded to retinitis pigmentosa, Choroideremia and Stargardt disease.
- Additional active program: KIO-104 for posterior non-infectious uveitis.
- KIO-101 and KIO-201 internal development leading to commercialization was stopped; the company is seeking partners for further development.
Financial Results and Key Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | No significant revenue reported | No significant revenue reported |
| Research and development expense | $1.1 million | $2.9 million |
| General and administrative expense | $1.4 million | $3.8 million |
| In-process R&D impairment | $1.9 million | $1.9 million |
| Change in fair value of contingent consideration | $1.5 million | $1.9 million |
| Total operating expenses | $5.9 million | $10.5 million |
| Net loss | $5.8 million | $10.2 million |
| Net loss attributable to common shareholders | $6.3 million | $10.8 million |
| Basic and diluted loss per share | $0.89 | $2.73 |
| Cash used in operating activities | Not separately provided | $7.0 million |
- Operating and net profit margins are not meaningful because the company has no significant revenue and recorded operating and net losses.
- Cash, cash equivalents and restricted cash totaled $5.4 million at September 30, 2023, compared with $6.0 million at December 31, 2022.
- Unrestricted cash and cash equivalents were $5.4 million; restricted cash was approximately $4,000.
- Net cash provided by financing activities was $6.5 million, primarily from a June public offering, equity-line purchases and warrant exercises.
- The company reported no material conventional debt in the balance sheet. Total liabilities were $7.8 million, including $5.5 million of contingent consideration and a $0.7 million deferred tax liability.
- Total assets were $15.9 million and stockholders’ equity was $8.1 million at September 30, 2023.
Material Changes Versus Prior Comparable Period
- Third-quarter net loss increased to $5.8 million from $5.1 million, primarily because of the $1.9 million in-process R&D impairment charge and a $1.2 million increase in the fair value of contingent consideration. Lower general and administrative and research and development expenses partially offset these items.
- Nine-month net loss improved to $10.2 million from $11.1 million. The improvement primarily reflected lower general and administrative expense, the absence of 2022 executive severance and favorable year-over-year changes in other income, partially offset by higher research spending, the impairment charge and increased contingent consideration expense.
- Research and development expense increased $0.3 million for the nine-month period, driven by higher KIO-301 and KIO-101 clinical activity and personnel costs, partly offset by lower preclinical and manufacturing spending.
- Cash used in operations declined to $7.0 million from $8.3 million, while financing cash inflows increased to $6.5 million from $5.4 million.
- Common shares outstanding increased to 7,689,240 at September 30, 2023 from 1,796,472 at December 31, 2022, primarily due to equity offerings and conversion of Series F preferred stock.
- The company recorded a $0.5 million deemed dividend attributable to a reset of the exercise price of certain warrants.
Guidance, Outlook, Risks and Unusual Items
- Management estimates that cash on hand at September 30, 2023 will fund planned operations into May 2024, although spending changes could materially alter the runway.
- The company has approximately $9.6 million available under an equity line of credit, subject to limitations, but has no committed external funding source and expects to require additional equity, debt, partnership, licensing or grant financing.
- Management states that recurring losses and expected future financing needs create substantial doubt about the company’s ability to continue as a going concern. The financial statements contain no adjustments for a possible failure to continue as a going concern.
- The $1.9 million impairment reduced the carrying value of in-process R&D after the strategic decision to stop internal development of KIO-101 and KIO-201 and pursue partnerships.
- Contingent consideration had a fair value of $5.5 million at September 30, 2023, with changes driven largely by revised probabilities of success for Bayon milestones associated with additional KIO-301 indications and Panoptes milestones associated with KIO-104.
- On July 18, 2023, Nasdaq notified the company that its stock price had failed to meet the $1.00 minimum bid requirement. The initial compliance period ends January 15, 2024, with a possible additional compliance period subject to Nasdaq requirements. Delisting could reduce liquidity and impair access to capital.
- Disclosure controls and procedures were not effective at September 30, 2023 because of previously identified material weaknesses. Remediation efforts, including new accounting software, approval workflows and enhanced technical accounting procedures, remained in process.
- The company terminated Mediolanum’s KIO-101 out-license in September 2023 for a $0.1 million termination fee and amended its SentrX arrangements to eliminate future KIO-201 milestone obligations.
- Subsequent events included new Austria and California office lease commitments and an amendment to the University of California license granting exclusive rights to a patent application covering certain KIO-301 formulations.
Important Facts for Investors to Verify
- Whether Kiora can raise sufficient capital before its projected May 2024 cash runway ends and on terms that do not cause excessive dilution or unfavorable licensing concessions.
- Progress, clinical results, regulatory status and funding requirements for KIO-301 and KIO-104, including the newly added Choroideremia and Stargardt indications.
- Whether KIO-101 and KIO-201 can be partnered after internal development was stopped and whether the impairment fully reflects their reduced carrying value.
- Whether the company regains Nasdaq minimum bid-price compliance and remains compliant with other listing requirements.
- Changes in the fair value and payment timing of the $5.5 million contingent consideration liability.
- Whether remediation of the identified material weaknesses is completed and operating effectively.
- The potential dilution from 13.1 million outstanding warrant shares, 0.8 million employee stock options, restricted stock and other reserved shares, compared with 7.7 million common shares outstanding at September 30, 2023.